USFDA Issues Form 483 With 11 Observations to Aurobindo Raleigh Plant
Aurobindo Pharma has announced that the US Food and Drug Administration (USFDA) issued a Form 483 with 11 observations to its Raleigh plant in North Carolina, operated by its subsidiary Aurolife Pharma LLC. The inspection was conducted from March 24 to April 10, 2025.
The observations are described as procedural and will be addressed through a comprehensive response within the required timeline, detailing corrective and preventive actions. Aurobindo emphasized its commitment to maintaining high-quality standards and stated that this development is not expected to impact current business operations or existing supplies from the facility.
This regulatory update highlights the importance of compliance in pharmaceutical manufacturing, with Aurobindo affirming its dedication to meeting USFDA standards.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$169/UNIT FOB
2026-10-19
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
India Proposes New GMP Rules for Clinical Trial and API Manufacturing
-
U.S. Exempts Critical Chemical Manufacturers from Emissions Rules for Two Years
-
China Releases 15th Five-Year Carbon-Peaking Action Plan, Pushing Coal Chemicals into a Mandatory Low-Carbon Upgrade Cycle
-
FDA Color Policy Uncertainty Opens a New Chapter for Food Ingredient Reform
-
Bayer and Syngenta Score Consecutive Regulatory and Legal Wins in the U.S.
-
South Korea Expands Mandatory GMO Labeling to Highly Processed Foods
-
Vera’s New Kidney Drug Wins FDA Approval, Carrying a $425,000 Annual Price
-
Four Fine Chemical Units of Huajin Aramco Project – HDPE, EO/EG, etc. – Reach Mechanical Completion
-
关于将二氟乙咪酯等16种物质列入《非药用类麻醉药品和精神药品目录》的公告 Announcement on the Inclusion of 16 Substances including Difluoroetomidate in the Catalogue of Non-Medicinal Narcotic Drugs and Psychotropic Substances
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
Recommend Reading
-
![UK’s £350 Million Critical Chemicals Fund Enters Formal Review, Offering Up to 50% Support Per Project]()
UK’s £350 Million Critical Chemicals Fund Enters Formal Review, Offering Up to 50% Support Per Project
-
![EU Chemicals Regulatory Update: Practical Compliance Actions Following ECHA January 2026 Developments]()
EU Chemicals Regulatory Update: Practical Compliance Actions Following ECHA January 2026 Developments
-
![FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers]()
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
![Trump Urges Ukraine to Halt Russian Refinery Strikes as Diesel Shortage Becomes a Global Policy Issue]()
Trump Urges Ukraine to Halt Russian Refinery Strikes as Diesel Shortage Becomes a Global Policy Issue
-
![EAEU Initiates Review of Anti-Dumping Measures on Chinese Titanium Dioxide, Suspends Duties During Investigation]()
EAEU Initiates Review of Anti-Dumping Measures on Chinese Titanium Dioxide, Suspends Duties During Investigation
-
![This week, the price of polyester bottle chips fluctuated and rose]()
This week, the price of polyester bottle chips fluctuated and rose
-
![February Acetic Acid Market Fluctuates]()
February Acetic Acid Market Fluctuates
-
![Demand Continues to Weaken, China's Acrylonitrile Market Fluctuates Downward]()
Demand Continues to Weaken, China's Acrylonitrile Market Fluctuates Downward
-
![Polystyrene (PS): Properties, Foam Applications, and Recycling Challenges]()
Polystyrene (PS): Properties, Foam Applications, and Recycling Challenges
-
![February phosphate market trend shows strong increase in China]()
February phosphate market trend shows strong increase in China
